Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ABUS | US
-0.06
-1.54%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.84
3.91
3.92
3.81
Arbutus Biopharma Corporation a biopharmaceutical company develops novel therapeutics for chronic Hepatitis B virus (HBV) infection SARS-CoV-2 and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729 a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens including HBsAg expression. The company's research and development programs include AB-161 an oral HBV RNA destabilizer; AB-101 an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses including COVID-19. It has licensing agreements with Gritstone Oncology Inc; Alnylam Pharmaceuticals Inc.; Qilu Pharmaceuticals Co Ltd; Assembly Biosciences Inc.; Acuitas Therapeutics Inc.; and Antios Therapeutics Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster Pennsylvania.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
28.8%1 month
53.3%3 months
42.0%6 months
43.0%-
-
5.90
0.06
0.05
-5.64
57.91
-
-80.99M
724.92M
724.92M
-
-1.24K
-
-62.90
-59.96
5.51
4.41
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.53
Range1M
1.07
Range3M
1.68
Rel. volume
0.41
Price X volume
2.45M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Immunome Inc | IMNM | Biotechnology | 13.17 | 790.92M | -2.44% | n/a | 1.09% |
89bio Inc | ETNB | Biotechnology | 7.19 | 772.52M | -0.96% | n/a | 5.31% |
Capricor Therapeutics Inc | CAPR | Biotechnology | 21.65 | 765.05M | 31.05% | n/a | 45.32% |
TNGX | TNGX | Biotechnology | 6.98 | 747.87M | -0.85% | n/a | 15.28% |
Opthea Limited | OPT | Biotechnology | 4.48 | 746.87M | -2.61% | n/a | -264.65% |
AbCellera Biologics Inc | ABCL | Biotechnology | 2.5 | 736.66M | 0.81% | n/a | 6.49% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 11.53 | 701.04M | 5.68% | n/a | 15.34% |
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 8.27 | 698.29M | 0.85% | n/a | 0.11% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.64 | 0.76 | Cheaper |
Ent. to Revenue | 57.91 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 5.90 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 41.98 | 74.67 | Lower Risk |
Debt to Equity | 0.06 | -1.82 | Expensive |
Debt to Assets | 0.05 | 0.26 | Cheaper |
Market Cap | 724.92M | 3.73B | Emerging |